Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Sanara MedTech in a research report issued on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($2.43) for the year, down from their previous estimate of ($0.98). Cantor Fitzgerald currently has a "Overweight" rating and a $46.00 target price on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share.
Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The business had revenue of $26.31 million for the quarter, compared to analysts' expectations of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.
Separately, HC Wainwright boosted their price target on Sanara MedTech from $50.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday, March 26th.
Get Our Latest Stock Report on SMTI
Sanara MedTech Price Performance
Shares of SMTI stock traded down $0.55 during mid-day trading on Friday, reaching $30.32. The company's stock had a trading volume of 7,066 shares, compared to its average volume of 23,161. Sanara MedTech has a 1-year low of $26.00 and a 1-year high of $39.08. The company has a market cap of $269.91 million, a P/E ratio of -30.69 and a beta of 1.37. The firm's 50-day moving average is $34.22 and its two-hundred day moving average is $33.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in SMTI. State Street Corp lifted its position in shares of Sanara MedTech by 9.2% during the third quarter. State Street Corp now owns 58,688 shares of the company's stock worth $1,775,000 after purchasing an additional 4,932 shares in the last quarter. Barclays PLC raised its position in Sanara MedTech by 323.0% in the 3rd quarter. Barclays PLC now owns 5,731 shares of the company's stock worth $174,000 after purchasing an additional 4,376 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company's stock worth $2,670,000 after buying an additional 3,755 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Sanara MedTech by 127.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company's stock valued at $123,000 after buying an additional 2,272 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of Sanara MedTech in the 4th quarter valued at $898,000. 8.10% of the stock is owned by institutional investors.
About Sanara MedTech
(
Get Free Report)
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
See Also
Before you consider Sanara MedTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.
While Sanara MedTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.